Chenyu Lin, Assistant Professor of Medicine at Duke University School of Medicine, shared on X:
“Important CAR T-cell debate (Brexu-cel vs. Obe-cel in ALL) featuring Ryan Cassaday and Nitin Jain!
- Brexu-cel has long-term outcomes, reliable manufacturing, and ease of use.
- Obe-cel’s unique kinetics grant a favorable toxicity profile with seemingly comparable efficacy.
With shoutouts to the great work coming out of Lori Muffly ROCCA studies.”
Source: Chenyu Lin/X